AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)

CME Available: https://auau.auanet.org/node/43009

At the conclusion of this activity, participants will be able to:

1. Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.

2. Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.

3. Diagram the treatment options for high-risk non-muscle invasive bladder cancer.

4. Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer.

5. Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.